Cidara Therapeutics Inks USD 780M Deal with J&J
The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&J came. Cidara Therapeutics has announced a deal with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 to prevent and treat seasonal and pandemic influenza.
Under the terms and conditions of the agreement, Janssen (J&J’s company) will pay Cidara an aggregate amount of USD 753 million (upfront USD 27 million) as budget for development of the candidate, milestone and regulatory payments along with royalties on sales. While Cidara will skim the candidate through ...
